Myocardial infarction

Published on 01/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1425 times

27

Myocardial infarction

Infarction is defined as the process by which necrosis (cell or tissue death) results from ischaemia (loss of blood supply). Infarction of cardiac muscle (myocardial infarction or MI) is one of the commonest causes of morbidity and mortality in adults living in industrialized societies.

Pathology

The underlying pathology in MI is atherosclerosis, an inflammatory process located within the arterial wall in the form of atheromatous plaques (Fig 27.1). These cause narrowing of the arterial lumen, resulting in reduced coronary perfusion, the clinical manifestation of which is chest pain (angina pectoris). If an unstable plaque ruptures, the released contents precipitate the formation of a clot. This process, known as thrombosis, may result in sudden complete occlusion of the affected artery and infarction of the area of myocardium it supplies.

Definitions

Acute coronary syndrome

The term acute coronary syndrome (ACS) refers to chest pain and other related symptoms attributed to impaired blood supply to the heart. It encompasses ST-segment elevation myocardial infarction (STEMI), non–ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The ST segment refers to part of the electrical tracing of the heart beat recorded on the electrocardiogram or ECG (Fig 27.2). Pathologically, it is almost always associated with rupture of an atherosclerotic plaque and partial or complete thrombosis of a coronary artery. In some instances ACS may occur from increased demands on the heart, e.g. with severe blood loss, anaemia, tachycardia or severe infections.

Myocardial infarction

The universal definition of acute myocardial infarction (AMI) has undergone changes in recent years in tandem with newer developments in the assays for diagnostic biomarkers. Table 27.1 briefly outlines the Experts Consensus Document on behalf of the Joint Task Force of European and American Cardiology Societies for the Redefinition of Myocardial Infarction.

Cardiac biomarkers

When myocardial cells die, they break up and release their contents. This is the basis for the role of cardiac biomarkers in MI diagnosis. Historically, various ‘cardiac enzymes’ have been used (Fig 27.3); however, at present, cardiac troponins are used in the diagnosis of MI. Troponin is a complex contractile protein comprising of three subunits: C, T and I. Troponin T and I are cardiospecific (therefore used in MI diagnosis; Tables 27.2 and 27.3), whereas C is also present in skeletal muscle. Troponins rise within a few hours on onset of symptoms and remain elevated for 1–2 weeks. This property enables early as well as late diagnosis. The diagnostic sensitivity of troponin reaches 100% 12 hours after onset of symptoms, i.e. MI can be excluded with confidence with a negative (undetectable) troponin if the blood sample is collected 12 hours or more after the onset of chest pain. Point-of-care devices are also available, which allow on-site measurement of troponin, but these tests are still relatively expensive.

Table 27.3

Troponins T and I contrasted

  Troponin T Troponin I
Molecular weight 37 kDa 22.5 kDa
Nature of protein Structural Catalytic
Kinetics of release Biphasic Only a single peak
Duration of elevation Up to 14 days 5–7 days
Number of assays One Several
Ontogeny May be expressed in skeletal muscle in utero Only ever expressed in myocardium

Crucially, any elevation of troponin i.e. detectable levels in the blood, especially with the newer ultra-sensitive assays, implies a greater risk of morbidity and mortality from a cardiac event over the next 30–60 days. Therefore its application has extended from just the diagnosis of MI to risk stratification and therapy modification in ACS. It is also worth noting that though troponins are considered very specific markers of ACS, they can also increase in other cardiovascular pathologies such as myocarditis, pulmonary embolism and stroke and non-cardiac conditions such as severe sepsis.

Share this: